Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of increasing gross motor activity in an individual comprising administering an effective dosage regime of hypocretin-1 or hypocretin 2 to a peripheral tissue in the individual sufficient to increase gross motor activity in the individual as measurable by an activity monitor;

wherein the individual is overweight, suffers from a weight disorder, or suffers from obesity.

2. (Original) The method of claim 1, wherein the individual has excess body weight before the administering step and the administering reduces the excess body weight.

3. (Original) The method of claim 1, wherein the individual has excess body weight before the administering step and the administering prevents the development of further excess body weight.

4. (Original) The method of claim 1, further comprising monitoring a sign of the excess body weight responsive to the administering.

5. (Original) The method of claim 4, wherein the sign of the excess body weight is a body mass index, waist circumference, waist to hip ratio, skin fold thickness, body density, body weight, or body fat percentage of the individual.

6. (Currently Amended) The method of claim 1, wherein the administering is by ~~cerebrospinal injection, intracerebroventricular injection,~~ intraparenchymal injection, intravenous infusion, intraperitoneal injection, transdermal delivery, intramuscular delivery, subcutaneous delivery, inhalation, nasal, rectal, or oral delivery.

7. (Original) The method of claim 1, wherein the individual suffers from a weight disorder.

8. (Original) The method of claim 7, wherein the weight disorder is due to a deficiency of a hypocretin, a hypocretin agonist, or a hypocretin receptor in the individual.

9. (Original) The method of claim 7, wherein the weight disorder is due to a deficiency in a hypocretin receptor transduction pathway in the individual.

10. (Original) The method of claim 1, wherein the individual suffers from obesity.

11. (Original) The method of claim 10, wherein obesity is determined based on a sign of excess body weight selected from the group consisting of body mass index, waist circumference, waist to hip ratio, skin fold thickness, body density, body weight, and body fat percentage.

12. (Original) The method of claim 10, wherein the individual has a body mass index of 30 or higher before beginning the administering step.

13. (Original) The method of claim 1, wherein the individual is overweight.

14. (Original) The method of claim 1, wherein the administering causes an increase in the individual's caloric output relative to the individual's caloric intake.

15. (Currently Amended) The method of claim 1, wherein the hypocretin ~~or agonist thereof~~ is administered with a pharmaceutically acceptable carrier as a pharmaceutical composition.

16. (Original) The method of claim 1, wherein the individual is free of narcolepsy.

17. (Currently Amended) A method of increasing locomotion in an individual, the method comprising administering an effective dosage regime of hypocretin-1 or hypocretin 2 to a peripheral tissue in the individual;

wherein the individual is overweight, suffers from a weight disorder, or suffers from obesity.

18-26. (Canceled)

27. (Currently Amended) A method of increasing locomotion in an individual, the method comprising administering an effective dosage regime of hypocretin-1 or hypocretin 2 to a peripheral tissue in the individual;

wherein the individual is overweight, suffers from a weight disorder, or suffers from obesity, and wherein the administering results in the increased locomotion in the individual.

28. (Canceled)

29. (Previously Presented) The method of claim 27, further comprising monitoring the locomotion in the individual responsive to the administering.

30-36. (Canceled)

37. (Currently Amended) A method of treating an individual who is overweight, suffers from a weight disorder, or suffers from obesity comprising administering an effective dosage regime of hypocretin-1 or hypocretin 2 to a peripheral tissue in the individual sufficient to increase gross motor activity in the individual as measurable by an activity monitor,

wherein the individual shows a behavioral symptom of a weight disorder, and wherein the behavioral symptom is selected from the group consisting of inactivity, overeating, and high calorie food selection.